Literature DB >> 29371047

Intracellular glutathione-depleting polymeric micelles for cisplatin prodrug delivery to overcome cisplatin resistance of cancers.

Yu Han1, Wei Yin2, Junjie Li1, Hong Zhao3, Zengshi Zha1, Wendong Ke1, Yuheng Wang1, Chuanxin He4, Zhishen Ge5.   

Abstract

The intrinsic or acquired cisplatin resistance of cancer cells frequently limits the final therapeutic efficacy. Detoxification by the high level of intracellular glutathione (GSH) plays critical roles in the majority of cisplatin-resistant cancers. In this report, we designed an amphiphilic diblock copolymer composed of poly(ethylene glycol) (PEG) and polymerized phenylboronic ester-functionalized methacrylate (PBEMA), PEG-b-PBEMA, which can self-assemble into micelles in aqueous solutions to load hydrophobic cisplatin prodrug (Pt(IV)). Pt(IV)-loaded PEG-b-PBEMA micelles (PtBE-Micelle) reverse cisplatin-resistance of cancer cells through improving cellular uptake efficiency and reducing intracellular GSH level. We found that the cellular uptake amount of platinum from PtBE-Micelle was 6.1 times higher than that of free cisplatin in cisplatin-resistant human lung cancer cells (A549R). Meanwhile, GSH concentration of A549R cells was decreased to 32% upon treatment by PEG-b-PBEMA micelle at the phenyl borate-equivalent concentration of 100μM. PtBE-Micelle displayed significantly higher cytotoxicity toward A549R cells with half maximal inhibitory concentration (IC50) of cisplatin-equivalent 0.20μM compared with free cisplatin of 33.15μM and Pt(IV)-loaded PEG-b-poly(ε-caprolactone) micelles of cisplatin-equivalent 0.75μM. PtBE-Micelle can inhibit the growth of A549R xenograft tumors effectively. Accordingly, PEG-b-PBEMA micelles show great potentials as drug delivery nanocarriers for platinum-based chemotherapy toward cisplatin-resistant cancers.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cisplatin; Drug delivery; Drug resistance; GSH depletion; Polymeric micelle

Mesh:

Substances:

Year:  2018        PMID: 29371047     DOI: 10.1016/j.jconrel.2018.01.019

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  7 in total

1.  "Pincer movement": Reversing cisplatin resistance based on simultaneous glutathione depletion and glutathione S-transferases inhibition by redox-responsive degradable organosilica hybrid nanoparticles.

Authors:  Boyi Niu; Yixian Zhou; Kaixin Liao; Ting Wen; Sixian Lao; Guilan Quan; Xin Pan; Chuanbin Wu
Journal:  Acta Pharm Sin B       Date:  2021-10-21       Impact factor: 14.903

2.  A Theranostic Nanocomplex Combining with Magnetic Hyperthermia for Enhanced Accumulation and Efficacy of pH-Triggering Polymeric Cisplatin(IV) Prodrugs.

Authors:  Yang Qu; Zhiqi Wang; Miao Sun; Tian Zhao; Xuanlei Zhu; Xiaoli Deng; Man Zhang; Ying Xu; Hongfei Liu
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-14

3.  GSH depletion liposome adjuvant for augmenting the photothermal immunotherapy of breast cancer.

Authors:  Zhanwei Zhou; Hui Wu; Ruoxi Yang; Alan Xu; Qingyan Zhang; Jingwen Dong; Chenggen Qian; Minjie Sun
Journal:  Sci Adv       Date:  2020-09-02       Impact factor: 14.136

4.  STAT3 regulated miR-216a promotes ovarian cancer proliferation and cisplatin resistance.

Authors:  Pengfei Jin; Yanjun Liu; Ruijuan Wang
Journal:  Biosci Rep       Date:  2018-08-29       Impact factor: 3.840

Review 5.  Harnessing Endogenous Stimuli for Responsive Materials in Theranostics.

Authors:  Alexander B Cook; Paolo Decuzzi
Journal:  ACS Nano       Date:  2021-02-08       Impact factor: 15.881

6.  Biomimetic Redox-Responsive Mesoporous Organosilica Nanoparticles Enhance Cisplatin-Based Chemotherapy.

Authors:  Fangman Chen; Fan Zhang; Yanbin Wang; Jiahui Peng; Lei Cao; Qian Mei; Mingfeng Ge; Li Li; Meiwan Chen; Wen-Fei Dong; Zhimin Chang
Journal:  Front Bioeng Biotechnol       Date:  2022-03-16

7.  A cancer-specific activatable theranostic nanodrug for enhanced therapeutic efficacy via amplification of oxidative stress.

Authors:  Xie-An Yu; Mi Lu; Yingping Luo; Yiting Hu; Ying Zhang; Zhiming Xu; Shuaishuai Gong; Yunhao Wu; Xiao-Nan Ma; Bo-Yang Yu; Jiangwei Tian
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.